Browse BTLA

Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00047 Immunoglobulin domain
Function

Lymphocyte inhibitory receptor which inhibits lymphocytes during immune response.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0042110 T cell activation
GO:0045785 positive regulation of cell adhesion
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-388841: Costimulation by the CD28 family
R-HSA-168256: Immune System
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BTLA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between BTLA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23692853LymphomaInhibit immunity (T cell function); immunotherapy targetBTLA was strongly expressed at the surface of resting Vγ9Vδ2 T cells and inversely correlated with T-cell differentiation. BTLA-HVEM blockade by monoclonal antibodies resulted in the enhancement of Vγ9Vδ2 T-cell receptor-mediated signaling, whereas BTLA-HVEM interaction led to a decrease in phosphoantigen-mediated proliferation by inducing a partial S-phase arrest. These data suggest that HVEM interaction with BTLA may play a role in lymphomagenesis by interfering with Vγ9Vδ2 T-cell proliferation.
20038811MelanomaInhibit immunity (T cell function)BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. Thus, BTLA activation inhibits the function of human CD8+ cancer-specific T cells, and appropriate immunotherapy may partially overcome this inhibition.
29353075Diffuse Large B-Cell LymphomaInhibit immunity (T cell function); resistant to immunotherapyBTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints. Our results suggest that BTLA+ T cells highly express other checkpoint molecules, including PD-1, TIM-3, LIGHT, and LAG-3. Taken together, our data provide the first evidence that increased BTLA predicts poor prognosis in patients with DLBCL, and blockade of BTLA with other checkpoints may potentially represent a new strategy for immunotherapy of DLBCL.
22205715MelanomaInhibit immunityHere, we report that the upregulation of the inhibitory molecule BTLA also plays a critical role in restricting NY-ESO-1-specific CD8(+) T-cell expansion and function in melanoma. BTLA-expressing PD-1(+)Tim-3(-) CD8(+) T cells represented the largest subset of NY-ESO-1-specific CD8(+) T cells in patients with melanoma. These cells were partially dysfunctional, producing less IFN-γ than BTLA(-) T cells but more IFN-γ, TNF, and interleukin-2 than the highly dysfunctional subset expressing all three receptors.
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BTLA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BTLA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0990.789
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4180.5
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1370.794
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5880.251
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.370.68
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8570.42
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2210.104
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.1570.0444
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2660.817
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8840.166
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0440.251
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.10.698
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BTLA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BTLA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BTLA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BTLA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BTLA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BTLA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBTLA
NameB and T lymphocyte associated
Aliases BTLA1; CD272; B and T lymphocyte attenuator; B- and T-lymphocyte-associated protein; CD antigen CD272; B- an ......
Chromosomal Location3q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BTLA collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.